Tags:Artificial IntelligenceBioTechDataDevelopmentDrugFutureHealthHumanInformationLabLifeTechnologyUniversity
NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of human, biological, pharmacological and clinical data points that the company has normalized and annotated. The company integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases.
Likes
69
Location: United States, San Mateo
Member count: 1-10
Phone: (650) 918-6363
Total raised: $3.5M

Investors 1

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
26.06.2013Series A$3.5M--

Mentions in press and media 13

DateTitleDescriptionCategoryAuthorSource
26.03.2018This is ho...An oft-quoted statistic is tha...--medcitynew...
09.01.2018Andy Slavi...“To some extent, [AI] is a bes...--medcitynew...
19.09.2015Bursting T...Michael Jin Contributor Micha...big data, ...Michael Ji...techcrunch...
04.11.2013Big data, ...So far, three papers have been...--medcitynew...
27.06.2013Stanford s...“NuMedii’s drug development ap...--medcitynew...
26.06.2013NuMedii Re...NuMedii, Inc., a Menlo Park, C...funding S...-finsmes.co...
07.02.2013Meet The N...Stanford’s student startup acc...StartXRyan Lawle...techcrunch...
31.12.2012Silicon Va...As the year draws to an end, S...-Christina ...venturebea...
03.10.2012Using data...The big data startup will use ...--medcitynew...
07.09.2012Stanford s...Watch live video from start x ...--medcitynew...
Show more